Physician profile
Timothy Davis Carter
NPI 1154311652
$6,160.98
in general payments reported to CMS, 2019-2025
45 companies · $50.89 in 2025
The $50.89 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,925 · 2020: $1,381 · 2021: $1,270 · 2022: $310 · 2023: $200 · 2024: $24.55 · 2025: $50.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.33 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $675.31 | 2019-2022 | |
| Intuitive Surgical, INC. | $549.08 | 2019 | |
| Abbvie INC. | $413.97 | 2019-2023 | Qulipta, Ubrelvy |
| Emd Serono, INC. | $359.08 | 2019-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $324.29 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Allergan, INC. | $284.24 | 2019-2021 | |
| Amgen INC. | $269.56 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $208.79 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $204.57 | 2019-2021 | |
| Genzyme Corporation | $202.07 | 2019-2020 | |
| Biogen, INC. | $193.49 | 2019-2020 | |
| Lilly USA, LLC | $164.18 | 2019-2023 | Amyvid |
| Sunovion Pharmaceuticals INC. | $163.70 | 2019-2020 | |
| Greenwich Biosciences, INC. | $162.26 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $149.17 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.